Recruiting

Testing a New Skin Medication for Children With Moderate-to-Severe Plaque Psoriasis

Plain-English translation of NCT07250802 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This study is testing a new oral medication called to see how well it works, how safe it is, and how children and teenagers with moderate-to-severe plaque psoriasis respond to it. In the first 16 weeks, some participants will receive the medication while others receive a placebo (a dummy pill with no active ingredient) to compare how well it works. After that, everyone will receive the medication for the remainder of the study.

Plaque psoriasis is a chronic skin condition that can significantly affect children's quality of life, and there is a need for safe and effective treatment options for young patients. This trial will help doctors understand whether this new medication could be a helpful option for children and teenagers with moderate-to-severe psoriasis.

Do you qualify?

You likely qualify if…

you are between 4 and 17 years old (the study starts with teenagers aged 12-17, then expands to younger children)
you have been diagnosed with plaque psoriasis for at least 6 months before joining
your plaque psoriasis is moderate-to-severe and covers at least 10% of your body
your psoriasis has been stable for at least 6 months (no major flares or changes)
you weigh at least 40 kilograms (88 pounds) if you are between 12 and 17 years old
you are up to date with all required vaccinations

You likely don't qualify if…

you have other types of psoriasis besides plaque psoriasis (such as pustular or erythrodermic psoriasis)
you have a history of tuberculosis infection or active tuberculosis symptoms
you have active or recent serious herpes virus infections
you have a history of chronic or recurrent bacterial infections or opportunistic infections
you have previously taken zasocitinib or other similar medications called TYK2 inhibitors

What participation looks like

You will take the medication by mouth once daily for up to 4 years and 2 months. During the first 16 weeks, you may receive the real medication or a placebo, with neither you nor the study team knowing which one you have; after that point, everyone receives the real medication. You will visit the study site multiple times throughout the trial for check-ups, blood tests, and skin assessments to see how the medication is working and monitor for any side effects. The entire study commitment includes a screening period, about 4 years of treatment visits, and a final 4-week safety follow-up.

AI-generated summary from trial data · Jun 17, 2026 · Not medical advice

Testing a New Skin Medication for Children With Moderate-to-Severe Plaque Psoriasis

What is this trial?

Do you qualify?

What participation looks like

Trial locations